Skip to main content
Erschienen in:

01.06.2008 | Leitthema

Behandlung von Patienten mit metastasierten Keimzelltumoren

verfasst von: Prof. Dr. C. Kollmannsberger, K. Oechsle, F. Honecker, F. Mayer, C. Bokemeyer

Erschienen in: Die Onkologie | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hodentumoren stellen insgesamt eine seltene Tumorentität dar. Die Inzidenz von Hodentumoren, insbesondere der Frühstadien, ist jedoch deutlich ansteigend. Die optimale Behandlung dieser Patienten erfordert die enge Kooperation von Onkologen, Urologen und Strahlentherapeuten an erfahrenen Zentren. Die Prognose von Hodentumorpatienten ist ausgezeichnet und Überlebensraten variieren abhängig von Tumorstadium und prognostischen Faktoren zwischen 50–99%. Die Behandlungsintensität für Hodentumorpatienten ist dem individuellen Tumorstadium und den vorliegenden Prognosefaktoren angepasst. Der vorliegende Artikel fasst die derzeitigen Behandlungskonzepte für Patienten mit metastasierten Hodentumoren unter Berücksichtigung der Empfehlungen der europäischen evidenzbasierten Konsensuskonferenzrichtlinien zusammen.
Literatur
1.
Zurück zum Zitat Mead G for the IGCCCG (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15: 594–603 Mead G for the IGCCCG (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15: 594–603
2.
Zurück zum Zitat Weissbach L, Bussar MR, Flechtner H et al. (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 37: 582–594PubMedCrossRef Weissbach L, Bussar MR, Flechtner H et al. (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 37: 582–594PubMedCrossRef
3.
Zurück zum Zitat Kuczyk M, Machtens S, Stief C, Jonas U (1999) Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT). Int J Cancer 83: 852–855PubMedCrossRef Kuczyk M, Machtens S, Stief C, Jonas U (1999) Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT). Int J Cancer 83: 852–855PubMedCrossRef
4.
Zurück zum Zitat Albers P, Siener R, Krege S et al. (2006) One course of adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germ-cell tumors (NSGCT): results of the German Prospective Multicenter Trial (Association of Urological Oncology [AUO]/German testicular cancer study group [GTCSG] Trial 01–94). J Clinl Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 24: 4512 Albers P, Siener R, Krege S et al. (2006) One course of adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germ-cell tumors (NSGCT): results of the German Prospective Multicenter Trial (Association of Urological Oncology [AUO]/German testicular cancer study group [GTCSG] Trial 01–94). J Clinl Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 24: 4512
5.
Zurück zum Zitat Donohue JP, Thornhill JA, Foster RS et al. (1993) Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149: 237–243PubMed Donohue JP, Thornhill JA, Foster RS et al. (1993) Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149: 237–243PubMed
6.
Zurück zum Zitat Sheinfeld J, Motzer RJ, Rabbani F et al. (2003) Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. [see comment]. J Urol 170: 1159–1162PubMedCrossRef Sheinfeld J, Motzer RJ, Rabbani F et al. (2003) Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. [see comment]. J Urol 170: 1159–1162PubMedCrossRef
7.
Zurück zum Zitat Williams SD, Stablein DM, Einhorn LH et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433–1438PubMed Williams SD, Stablein DM, Einhorn LH et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433–1438PubMed
8.
Zurück zum Zitat Weissbach L, Hartlapp JH (1991) Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 146: 1295–1298PubMed Weissbach L, Hartlapp JH (1991) Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol 146: 1295–1298PubMed
9.
Zurück zum Zitat Williams SD, Birch R, Einhorn LH et al. (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440PubMed Williams SD, Birch R, Einhorn LH et al. (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440PubMed
10.
Zurück zum Zitat Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 16: 702–706PubMed Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 16: 702–706PubMed
11.
Zurück zum Zitat Wit R de, Roberts JT, Wilkinson P et al. (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19: 1629–1640PubMed Wit R de, Roberts JT, Wilkinson P et al. (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19: 1629–1640PubMed
12.
Zurück zum Zitat Fossa SD, Wit R de, Roberts JT et al. (2003) Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 21: 1107–1118PubMedCrossRef Fossa SD, Wit R de, Roberts JT et al. (2003) Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 21: 1107–1118PubMedCrossRef
13.
Zurück zum Zitat Bokemeyer C, Kohrmann O, Tischler J et al. (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‚good-risk‘ metastatic non-seminomatous germ cell tumors. Ann Oncol 7: 1015–1021PubMed Bokemeyer C, Kohrmann O, Tischler J et al. (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‚good-risk‘ metastatic non-seminomatous germ cell tumors. Ann Oncol 7: 1015–1021PubMed
14.
Zurück zum Zitat Horwich A, Sleijfer DT, Fossa SD et al. (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844–1852PubMed Horwich A, Sleijfer DT, Fossa SD et al. (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844–1852PubMed
15.
Zurück zum Zitat Wit R de, Stoter G, Kaye SB et al. (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15: 1837–1843PubMed Wit R de, Stoter G, Kaye SB et al. (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15: 1837–1843PubMed
16.
Zurück zum Zitat Loehrer-PJ Sr, Johnson D, Elson P et al. (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 13: 470–476PubMed Loehrer-PJ Sr, Johnson D, Elson P et al. (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 13: 470–476PubMed
17.
Zurück zum Zitat Culine S, Kerbrat P, Kramar A et al. (2007) Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 18: 917–924PubMedCrossRef Culine S, Kerbrat P, Kramar A et al. (2007) Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 18: 917–924PubMedCrossRef
18.
Zurück zum Zitat Kondagunta GV, Bacik J, Bajorin D et al. (2005) Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 23: 9290–9294PubMedCrossRef Kondagunta GV, Bacik J, Bajorin D et al. (2005) Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 23: 9290–9294PubMedCrossRef
19.
Zurück zum Zitat Wit R de, Louwerens M, Mulder PHM de et al. (1999) Management of intermediate prognosis germ cell cancer: results of a phase I/II study of taxol-BEP. Int J Cancer 83: 831–833PubMedCrossRef Wit R de, Louwerens M, Mulder PHM de et al. (1999) Management of intermediate prognosis germ cell cancer: results of a phase I/II study of taxol-BEP. Int J Cancer 83: 831–833PubMedCrossRef
20.
Zurück zum Zitat Nichols CR, Catalano PJ, Crawford ED et al. (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16: 1287–1293PubMed Nichols CR, Catalano PJ, Crawford ED et al. (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16: 1287–1293PubMed
21.
Zurück zum Zitat Kaye SB, Mead GM, Fossa SD et al. (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16: 692–701PubMed Kaye SB, Mead GM, Fossa SD et al. (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16: 692–701PubMed
22.
Zurück zum Zitat Wit R de, Stoter G, Sleijfer DT et al. (1995) Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71: 1311–1314PubMed Wit R de, Stoter G, Sleijfer DT et al. (1995) Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71: 1311–1314PubMed
23.
Zurück zum Zitat Culine J, Kramar A, Théodore C et al. (2008) Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26: 421–427PubMedCrossRef Culine J, Kramar A, Théodore C et al. (2008) Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26: 421–427PubMedCrossRef
24.
Zurück zum Zitat Nichols CR, Williams SD, Loehrer PJ et al. (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9: 1163–1172PubMed Nichols CR, Williams SD, Loehrer PJ et al. (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9: 1163–1172PubMed
25.
Zurück zum Zitat Schmoll HJ, Kollmannsberger C, Metzner B et al. (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21: 4083–4091PubMedCrossRef Schmoll HJ, Kollmannsberger C, Metzner B et al. (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21: 4083–4091PubMedCrossRef
26.
Zurück zum Zitat Bokemeyer C, Kollmannsberger C, Meisner C et al. (1999) First-line high-dose chemotherapy compared to standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched pair analysis. J Clin Oncol 17: 3450–3456PubMed Bokemeyer C, Kollmannsberger C, Meisner C et al. (1999) First-line high-dose chemotherapy compared to standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched pair analysis. J Clin Oncol 17: 3450–3456PubMed
27.
Zurück zum Zitat Motzer RJ, Nichols CJ, Margolin KA et al. (2007) Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25: 247–256PubMedCrossRef Motzer RJ, Nichols CJ, Margolin KA et al. (2007) Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25: 247–256PubMedCrossRef
28.
Zurück zum Zitat Mazumdar M, Bajorin DF, Bacik J et al. (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19: 2534–2541PubMed Mazumdar M, Bajorin DF, Bacik J et al. (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19: 2534–2541PubMed
29.
Zurück zum Zitat Fizazi K, Culine S, Kramar A et al. (2004) Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22: 3868–3876PubMedCrossRef Fizazi K, Culine S, Kramar A et al. (2004) Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22: 3868–3876PubMedCrossRef
30.
Zurück zum Zitat Toner GC, Stockler MR, Boyer MJ et al. (2001) Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357: 739–745PubMedCrossRef Toner GC, Stockler MR, Boyer MJ et al. (2001) Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357: 739–745PubMedCrossRef
31.
Zurück zum Zitat Collette L, Sylvester RJ, Stenning SP et al. (1999) Impact of the treating institution on survival of patients with „poor-prognosis“ metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party [see comments]. J Natl Cancer Inst 91: 839–846PubMedCrossRef Collette L, Sylvester RJ, Stenning SP et al. (1999) Impact of the treating institution on survival of patients with „poor-prognosis“ metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party [see comments]. J Natl Cancer Inst 91: 839–846PubMedCrossRef
32.
Zurück zum Zitat Feuer EJ, Sheinfeld J, Bosl GJ (1999) Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst 91: 816–818PubMedCrossRef Feuer EJ, Sheinfeld J, Bosl GJ (1999) Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst 91: 816–818PubMedCrossRef
33.
Zurück zum Zitat Albers P, Weissbach L, Krege S et al. (2004) Predictions of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 171: 1835–1838PubMedCrossRef Albers P, Weissbach L, Krege S et al. (2004) Predictions of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 171: 1835–1838PubMedCrossRef
34.
Zurück zum Zitat Mosharafa AA, Foster RS, Leibovich BC et al. (2003) Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 169: 2126–2128PubMedCrossRef Mosharafa AA, Foster RS, Leibovich BC et al. (2003) Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 169: 2126–2128PubMedCrossRef
35.
Zurück zum Zitat De Santis M, Becherer A, Bokemeyer C et al. (2004) 2–18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the Prospective Multicentric SEMPET Trial. J Clin Oncol 22: 1034–1039CrossRef De Santis M, Becherer A, Bokemeyer C et al. (2004) 2–18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the Prospective Multicentric SEMPET Trial. J Clin Oncol 22: 1034–1039CrossRef
36.
Zurück zum Zitat Debono DJ, Heilman DK, Einhorn LH, Donohue JP (1997) Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors [see comments]. J Clin Oncol 15: 1455–1464PubMed Debono DJ, Heilman DK, Einhorn LH, Donohue JP (1997) Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors [see comments]. J Clin Oncol 15: 1455–1464PubMed
37.
Zurück zum Zitat Steyerberg EW, Gerl A, Fossa SD et al. (1998) Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16: 269–274PubMed Steyerberg EW, Gerl A, Fossa SD et al. (1998) Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16: 269–274PubMed
38.
Zurück zum Zitat Hartmann JT, Candelaria M, Kuczyk MA et al. (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33: 843–847PubMedCrossRef Hartmann JT, Candelaria M, Kuczyk MA et al. (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33: 843–847PubMedCrossRef
39.
Zurück zum Zitat Toner GC, Panicek DM, Heelan RT et al. (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8: 1683–1694PubMed Toner GC, Panicek DM, Heelan RT et al. (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8: 1683–1694PubMed
40.
Zurück zum Zitat Stephenson AJ, Bosl GJ, Motzer RJ et al. (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23: 2781–2788PubMedCrossRef Stephenson AJ, Bosl GJ, Motzer RJ et al. (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23: 2781–2788PubMedCrossRef
41.
Zurück zum Zitat Fizazi K, Tjulandin S, Salvioni R et al. (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy–results from an international study group. J Clin Oncol 19: 2647–2657PubMed Fizazi K, Tjulandin S, Salvioni R et al. (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy–results from an international study group. J Clin Oncol 19: 2647–2657PubMed
42.
Zurück zum Zitat Bosl GJ, Geller NL, Bajorin D et al. (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6: 1231–1238PubMed Bosl GJ, Geller NL, Bajorin D et al. (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6: 1231–1238PubMed
43.
Zurück zum Zitat Bajorin DF, Sarosdy MF, Pfister DG et al. (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11: 598–606PubMed Bajorin DF, Sarosdy MF, Pfister DG et al. (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11: 598–606PubMed
44.
Zurück zum Zitat Ozols RF, Ihde DC, Linehan WM et al. (1988) A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6: 1031–1040PubMed Ozols RF, Ihde DC, Linehan WM et al. (1988) A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6: 1031–1040PubMed
45.
Zurück zum Zitat Wozniak AJ, Samson MK, Shah NT et al. (1991) A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 9: 70–76PubMed Wozniak AJ, Samson MK, Shah NT et al. (1991) A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 9: 70–76PubMed
Metadaten
Titel
Behandlung von Patienten mit metastasierten Keimzelltumoren
verfasst von
Prof. Dr. C. Kollmannsberger
K. Oechsle
F. Honecker
F. Mayer
C. Bokemeyer
Publikationsdatum
01.06.2008
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 6/2008
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-008-1366-5

Weitere Artikel der Ausgabe 6/2008

Die Onkologie 6/2008 Zur Ausgabe

Einführung zum Thema

Keimzelltumoren des Mannes

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.